Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.

Pharmaceutical research - 1 Aug 2017

Luzum Jasmine A, Sweet Kevin M, Binkley Philip F, Schmidlen Tara J, Jarvis Joseph P, Christman Michael F, Sadee Wolfgang, Kitzmiller Joseph P

Abstract excerpt

PURPOSE: This study examined whether a CYP2D6 polymorphism (CYP2D6*4) was related to beta-blocker maintenance dose in patients with heart failure. METHODS: Logistic regression modeling was utilized in a retrospective chart-review analysis of heart-failure patients (60% Male, 90% of European descent) to assess whether CYP2D6*4 (non-functional CYP2D6 allele present in 1 of 5 individuals of European descent) is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenergic beta-Antagonists
Share to Aged, 80 and over

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carbazoles

Share to Cytochrome P-450 CYP2D6

Share to Dose-Response Relationship, Drug

Share to Heart Failure

Share to Metoprolol

Share to Propanolamines

Source

Open in PubMed Open full text

Identifiers

PMID: 28181117
DOI: 10.1007/s11095-017-2104-8
PMCID: PMC5500390

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2D6 Genetic Variation and Beta-Blocker Maintenance Dose in Patients with Heart Failure.PMID 28181117Read ↗

Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy.Semantic proximity Read ↗

Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure.Semantic proximity Read ↗

The relevance of CYP2D6 genetic polymorphism on chronic metoprolol therapy in cardiovascular patients.Semantic proximity Read ↗

Impact of genotype-predicted CYP2D6 metabolism on clinical effects and tolerability of metoprolol in patients after myocardial infarction - a prospective observational study.Semantic proximity Read ↗

Genetic variation in the CYP2D6 gene is associated with a lower heart rate and blood pressure in beta-blocker users.Semantic proximity Read ↗

Genetic Variation of Hepatic Enzymes Influence on β-Blocker Dose in Patients With Reduced Ejection Fraction Heart Failure.Semantic proximity Read ↗

Impact of CYP2D6 Polymorphisms on Clinical Efficacy and Tolerability of Metoprolol TartrateSemantic proximity Read ↗

CYP2D6 polymorphism and its impact on the clinical response to metoprolol: A systematic review and meta-analysis.Semantic proximity Read ↗

beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure.Semantic proximity Read ↗

An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF substudy.Semantic proximity Read ↗

Effect of the CYP2D6 genotype on metoprolol metabolism persists during long-term treatment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.